Drugs / 11C-ER176
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03912428 | Jun 2019 → Jun 2024 | idiopathic inflammatory myopathy, rheumatoid arthritis | National Institute of Mental Health (NIMH) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03705715 | May 2017 → Aug 2028 expected | psychiatric disorder | The University of Texas Health Science Center, Houston | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03744312 | Sep 2018 → Jul 2022 | Alzheimer disease | Columbia University | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04840979 | May 2021 → Dec 2026 expected | Alzheimer disease | Columbia University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04576793 | Nov 2020 → May 2027 expected | Alzheimer disease | Columbia University | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04762719 | May 2021 → Mar 2022 | diabetes mellitus, gastroparesis | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 11C-ER176 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04762719 ↗ |
| Modality | Diagnostic / imaging agent | “radiotracer” NCT03705715 ↗ |
| Route | Intravenous | “injected into subjects' veins during PET scanning” NCT03705715 ↗ |
| Target | TSPO | “specifically bind translocator protein (TSPO)” NCT03705715 ↗ |